Tempus AI (NASDAQ:TEM) Sees Unusually-High Trading Volume - Here's Why

Shares of Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) saw an uptick in trading volume on Tuesday . 12,338,586 shares changed hands during trading, an increase of 5% from the previous session's volume of 11,781,585 shares.The stock last traded at $74.17 and had previously closed at $68.36.Wall Street Analysts Forecast GrowthHealth-Tech Revival: 3 Stocks Set for a Big 2025 ReboundA number of brokerages recently commented on TEM. Wolfe Research began coverage on Tempus AI in a research note on Friday, December 13th. They set an "outperform" rating and a $60.00 price objective for the company. Guggenheim began coverage on Tempus AI in a research note on Monday, December 9th. They set a "buy" rating and a $74.00 price objective for the company. Piper Sandler restated a "neutral" rating and set a $70.00 price objective (up from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Needham & Company LLC restated a "buy" rating and set a $56.00 price objective on shares of Tempus AI in a research note on Tuesday, January 14th. Finally, TD Cowen reissued a "buy" rating and issued a $74.00 price target (up previously from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $58.55.View Our Latest Stock Analysis on Tempus AITempus AI Price PerformanceMarketBeat Week in Review – 01/20 - 01/24The firm has a 50 day moving average of $44.60 and a 200-day moving average of $49.36. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Insiders Place Their BetsIn other Tempus AI news, major shareholder Bradley A. Keywell sold 265,000 shares of the company's stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $35.10, for a total value of $9,301,500.00. Following the transaction, the insider now directly owns 15,218,365 shares of the company's stock, valued at $534,164,611.50. This represents a 1.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Ryan M. Bartolucci sold 13,770 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $60.00, for a total value of $826,200.00. Following the transaction, the chief accounting officer now directly owns 57,237 shares in the company, valued at approximately $3,434,220. This represents a 19.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 2,229,449 shares of company stock valued at $102,293,124 in the last three months. Institutional Trading of Tempus AITempus AI: A Game-Changer in AI-Powered HealthcareHedge funds and other institutional investors have recently added to or reduced their stakes in the business. First Horizon Advisors Inc. acquired a new stake in Tempus AI in the 3rd quarter valued at approximately $30,000. Farther Finance Advisors LLC acquired a new stake in Tempus AI in the 4th quarter valued at approximately $34,000. FNY Investment Advisers LLC acquired a new stake in Tempus AI in the 4th quarter valued at approximately $67,000. IFP Advisors Inc acquired a new stake in Tempus AI in the 4th quarter valued at approximately $76,000. Finally, US Bancorp DE acquired a new stake in Tempus AI in the 4th quarter valued at approximately $80,000. Institutional investors and hedge funds own 24.22% of the company's stock. About Tempus AI (Get Free Report)Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.See AlsoFive stocks we like better than Tempus AIWhat is the S&P/TSX Index?META Stock: Insider Selling Ramps Up—What It Means for InvestorsWhat is MarketRank™? How to Use it3 Chip Stocks Still Trading 50% Below Their 52-Week HighsInvesting In Automotive StocksU.S. Steel: Will Trump-Backed Nippon Investment Drive Upside?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Where Should You Invest $1,000 Right Now?Before you make your next trade, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.They believe these five stocks are the five best companies for investors to buy now...See The Five Stocks Here Should You Invest $1,000 in Tempus AI Right Now?Before you consider Tempus AI, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.While Tempus AI currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here